TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

 TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

Shots:

  • Hongqi to get a license to commercialize pretomanid as part of the three-drug “BPaL” regimen to treat a highly drug-resistant form of tuberculosis in People’s Republic of China
  • The collaboration is a part of TB Alliance’s global commercialization strategy for pretomanid, complementing its previous agreement with Mylan & Macleods to commercialize pretomanid as part of the BPaL regimen in other countries
  • Pretomanid is an anti-tuberculosis therapy & a part of BPaL (bedaquiline, pretomanid and linezolid) regimen, studied in P-III Nix-TB study and has received FDA’s approval as a combination therapy in Aug’2019

Click here ­to­ read full press release/ article | Ref: TB Alliance | Image: TB Alliance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post